Home Products Industries Applications Solutions Support Insights Contact Us
Back to Blog
May 27, 2019·1 min read
Aquatic risks from human pharmaceuticals-modelling temporal trends of carbamazepine and ciprofloxacin at the global scale

Aquatic risks from human pharmaceuticals-modelling temporal trends of carbamazepine and ciprofloxacin at the global scale

ENVIRONMENTAL RESEARCH LETTERS

The post appeared first on .

Source: Water Feed

Frequently Asked Questions

What human pharmaceuticals are identified as significant aquatic risks globally?

The study highlights carbamazepine and ciprofloxacin as two widely detected and regulatory relevant human pharmaceuticals posing aquatic risks. While carbamazepine risks were generally low (AR < 0.1), ciprofloxacin showed much higher aquatic risks, exceeding 1 in 223 out of 449 freshwater ecoregions by 2015.

How have aquatic risks from human pharmaceuticals changed over the past two decades?

Aquatic risks due to exposure to human pharmaceuticals like carbamazepine and ciprofloxacin typically increased 10-20 fold between 1995 and 2015. This significant rise underscores the growing challenge for water purification systems globally, as human consumption and environmental persistence contribute to higher concentrations.

Which pharmaceutical, carbamazepine or ciprofloxacin, presents a higher aquatic risk?

Ciprofloxacin presents a significantly higher aquatic risk compared to carbamazepine. In 2015, ciprofloxacin’s Aquatic Risk (AR) exceeded 1 for 223 out of 449 freshwater ecoregions, indicating widespread concern. In contrast, carbamazepine’s AR was typically low (<0.1), though some densely populated or arid regions showed higher levels up to 1.1.

How are global aquatic risks of pharmaceuticals like carbamazepine and ciprofloxacin modeled?

Aquatic risks are modeled using a three-step procedure: first, predicting country- and year-specific per capita consumption; second, calculating spatially explicit freshwater concentrations via mass balance models for human, wastewater treatment, and environmental fate; and finally, dividing these concentrations by regulatory limit values derived from toxicity tests to determine ecoregion-specific risks.

What advanced water treatment solutions address pharmaceutical contamination in aquatic environments?

Addressing pharmaceutical contamination requires advanced water treatment technologies, particularly for commercial and industrial applications. AMPAC USA’s reverse osmosis (RO) and specialized purification systems are engineered to remove a broad spectrum of contaminants, including complex pharmaceutical compounds, ensuring safe and compliant water for diverse sectors like municipalities and food & beverage. Our 30+ years of field experience confirm the necessity of robust solutions.

Scroll to Top